Kailera Therapeutics (Nasdaq: KLRA) has completed enrollment in its KaiNETIC global Phase 3 clinical program, evaluating ribupatide injection (KAI-9531), an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE